RDA™Trial in Quebec, Canada completed
The Tumour RDA pilot study in Quebec, led by Dr. Jean-Francois Boileau of Montreal Jewish General Hospital, has been completed.
The two most important findings confirmed by the trial are RNA disruption can be detected as early as following the first cycle of chemotherapy treatment and the test can be performed with fine needle aspiration (FNA) biopsies versus core biopsies. FNAs can be performed in a doctor’s office making it easier for patients and more efficient.
"We are very pleased we met objectives for the pilot study by confirming optimal timing for the biopsy and the feasibility of FNA biopsies," said Dr. Boileau. "RDA is a very promising assay with potential to tailor the treatment for breast cancer patients around the world." Dr. Boileau will present the results of this research at a meeting of breast cancer researchers in Toronto in May. Dr. Boileau is a surgical oncologist and clinician scientist at the Montreal Jewish General Hospital. He is an assistant professor in the Department of Surgery at McGill University.
“We continue to build the evidence required by clinicians to utilize RDA in breast cancer chemotherapy treatment. RDA provides information to clinicians critical to treatment decisions,” said Dr. Ken Pritzker, President and CEO of Rna Diagnostics.
German Breast Group Clinical Trial
The German Breast Group (GBG) has approved the protocol for the “RNA Disruption Assay: Tumour Response Guide for Response Guided Breast Cancer Therapy" clinical trial to be conducted at the Luisenkrankenhaus hospital in Düsseldorf. Clinical Advisory Board member and Managing Director of GBG, Gunter von Minckwitz, is the Principle Investigator for the trial which will study RDA in 200 patients treated with neoadjuvant chemotherapy.
University of Guelph Canine study completed
A study of canine lymphoma utilizing RDA, in partnership with the University of Guelph Institute for Comparative Cancer Investigation and the Ontario Veterinary College has been completed and the data has been analyzed. Next steps include following the dogs in the study to determine outcomes.
"This sort of collaborative trial that uses naturally occurring cancer in dogs as a translational model for human oncology is one of the main aims of the ICCI. We are excited by the opportunity this study presents to improve our understanding of canine lymphoma responses to chemotherapy, and we look forward to analyzing the final outcome data with our colleagues at Rna Diagnostics," said Dr. Brenda Coomber of the OVC.
Lymphoma is one of the most prevalent cancers for dogs, and is frequently treated with combination chemotherapy. While standard of care CHOP protocol is highly effective at inducing initial remission in most dogs, approximately 60% of treated dogs will either fail to achieve initial remission, or will relapse within 6 months. Second line 'rescue' therapy can be successful, but at this time there is no way of identifying which dogs should abandon CHOP and switch to rescue regimes, other than waiting for them to fail to achieve remission or to relapse early.
Future clinical trials may explore how best to use this biomarker to choose optimal treatment for all dogs with lymphoma. It is also possible that RDA analysis will be informative for treatment outcome in other types of companion animal cancer. The Animal Cancer Centre at OVC treats hundreds of canine cancer patients annually.
Rna Diagnostics Connects with Clinicians
Rna Diagnostics attended the San Antonio Breast Cancer Symposium (SABCS) this year, meeting with over two dozen breast oncologists from leading research institutions around the world. Rna Diagnostics received strong, positive interest in RDA and is pursuing collaboration opportunities with clinical oncology groups in North America, Europe and Asia.
SABCS provides state-of-the-art information on breast cancer research attended by a broad international audience of academic and private researchers and physicians from over 90 countries. This international symposium is directed primarily towards academic and private physicians and researchers involved in breast cancer in medical, surgical, gynecologic, and radiation oncology, as well as other appropriate health care professionals.